Stasinos Chr. Sikalias · The science of compounding

Rosemary essential oil alcoholic solution 5% v/v

CGR-ES-076 · FN/2006/PO/035 ALCOHOL DE ROMERO AL 5%

For local reviewCGR-ES-076Spain · AEMPS

Documented bibliographic addition; requires local scientific approval before use as a master formulation record.

Dosage formSolution for external pharmaceutical use
Reference batch100 mL
Monograph version5.0
Source packagev5

Source formula

IngredientSource quantity
Rosemary essential oil5 mL
Ethanol 96%q.s. ad 100 mL

Quantities refer to the source batch. This website does not automatically scale formulas, assign doses or calculate BUD.

Description

Documented in source

Clear, colourless liquid with the odour of rosemary essential oil.

References: [1]

Use and action

Documented in source

Topical rub for symptomatic relief of muscle and joint pain, as described by AEMPS.

References: [1]

Specifications

Partial evidence

Clear, colourless liquid with the odour of rosemary essential oil. Quantities/raw-material quality follow §3. No specific numerical finished-product assay limit is provided.

References: [1]

Light

Documented in source

The finished preparation is stored protected from light under the monograph.

References: [1]

Air

Partial evidence

Ethanol generates vapour; limit time in open vessels. Evaporation can change composition (editorial process assessment).

References: [4]

Water and solubility

Partial evidence

Ethanol is miscible with water. This does not establish that all dissolved actives remain soluble after dilution.

References: [4]

Humidity

Not established

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

Temperature

Partial evidence

Finished-product storage: Below 30°C; protect from light and moisture as stated in the leaflet. Processing follows the method-specific temperatures.

References: [1]

pH and related incompatibilities

Not established

No specific finished-product information is established in the reviewed sources. Additional evidence is required before defining a specification.

References: [1]

Other incompatibilities

Partial evidence

Ethanol is incompatible with strong oxidants.

References: [4]

Ingredient-specific information

Partial evidence

Exact identities: Αιθέριο έλαιο δενδρολίβανου / Rosemary essential oil; Αιθανόλη 96% / Ethanol 96%. Use pharmacopoeial raw materials of the referenced edition, with CoA verification. Do not arbitrarily change salt, hydration state or strength. Record the actual q.s. amount in the batch.

References: [1]

Compounding conditions

Documented in source

Laboratory environment under the referenced AEMPS procedure: 25±5°C and relative humidity ≤60%, unless the specific formulation requires otherwise. Room temperature differs from processing temperature.

References: [2]

Personal protective equipment

Partial evidence

Clean protective clothing and head covering under AEMPS PN/L/PG/002/00. Use suitable gloves where contact is possible and respiratory/eye protection where powder handling requires it. Exact glove material, ventilation and respiratory protection must follow the SDS and local exposure assessment.

References: [3]

Risks and precautions

Partial evidence

Possible skin sensitisation/irritation and high alcohol content. Exact essential-oil identity is necessary.
Ethanol: flammable vapour; control ignition sources and provide suitable ventilation. Final classification depends on concentration/mixture.

References: [1] · [4]

BUD rationale

Partial evidence

The specific monograph states 3 months under its specified conditions. This is a source period, not independently verified stability of the local batch. Match composition, preservative, container and storage, check applicable requirements and obtain responsible approval. The actual date remains blank.

References: [1]

Bases and dependencies

Documented in source

No separate compound base is required in the explicit formula.

References: [1]

Equipment

Editorial checklist

Balance with suitable resolution, mortar/spatula, suitable mixing vessels and final container. Add volumetric equipment for mL, a controlled water bath where melting is specified and a suitable filter where required. Analytical equipment follows the QC methods.

References: [2]

Preparation procedure

Documented in source

1. Measure 5 mL pharmacopoeial-grade rosemary essential oil.
2. Dissolve in part of the 96% ethanol.
3. Make up to 100 mL with 96% ethanol and mix.

References: [1] · [2]

Observations

Partial evidence

Contains 5 mL essential oil, not 5 g herbal extract or tincture.

References: [1]

Packaging

Documented in source

Opaque, hermetically closed bottle.

References: [1]

Labelling

editorial_specimen

Rosemary essential oil alcoholic solution 5% v/v
Quantity: _____ · Batch: _____ · Prepared: _____ · Use by: _____
External use only. Storage: Below 30°C; protect from light and moisture as stated in the leaflet.
Patient/directions or laboratory use: _____ · Pharmacy/telephone: _____
Flammable. Keep away from flames. Do not swallow.
Specimen for pharmacist adaptation; not a final approved label.

References: [1] · [4]

Quality control

Partial evidence

Under AEMPS: organoleptic properties and final mass and/or volume. For batches: colour RFE 2.2.2, clarity/opalescence RFE 2.2.1, relative density RFE 2.2.5, pH under PN/L/CP/001/00 and microbiological testing under RFE 5.1.4. This formula provides no numerical pH/density limits or specific active assay.

References: [1] · [2]

Storage

Documented in source

Below 30°C; protect from light and moisture as stated in the leaflet.

References: [1]

Dispensing and directions

Documented in source

Cutaneous use only; a small amount with gentle rubbing several times daily according to the source. Stop if irritation occurs. Do not use with ingredient hypersensitivity. The source provides no specific paediatric regimen.

References: [1]

Sources and traceability

  1. FN/2006/PO/035 ALCOHOL DE ROMERO AL 5%

    FN/2006/PO/035 · Master formula §§3–4; packaging/storage §5; description §6; period §7; use/precautions §§8–12 and patient leaflet · A1 official formulary

    Review date reported in supplied metadata: 2026-09-10

  2. PN/L/FF/007/00 ELABORACIÓN DE SOLUCIONES

    PN/L/FF/007/00 · §4.3 environment; §4.4 method; §4.6 controls · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  3. PN/L/PG/002/00 INDUMENTARIA

    PN/L/PG/002/00 · Clothing and protective equipment · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  4. niosh_ethanol

    Official agency page · Raw-material properties, handling and incompatibilities · A2 official technical guidance

    Review date reported in supplied metadata: 2026-09-10

  5. AEMPS — Aviso legal

    Policy checked 2026-09-10 · Reuse conditions · Rights policy, not clinical evidence

    Review date reported in supplied metadata: 2026-09-10

  6. BOE — Real Decreto 1495/2011, artículos 7–10 y anexo

    Policy checked 2026-09-10 · Reuse conditions · Rights policy, not clinical evidence

    Review date reported in supplied metadata: 2026-09-10

Provenance and reuse

Source: Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), Formulario Nacional. Original Greek/English rendering and restructuring: Greek Formulary Sikalias, Stasinos Chr. Sikalias, compounding.gr. Reuse basis: AEMPS legal notice and RD 1495/2011, Articles 7–10/Annex. Composition and units retained; references, distinct editorial notes and blank batch fields added. AEMPS endorsement is not implied. Edition code appears in the reference; NIPO 134-20-002-3 / 090-22-245-5. The PDFs do not state an exact internal revision date. Access checked 10 September 2026. CDC/NIOSH sources are freely available from CDC; brief technical paraphrases imply no CDC endorsement.

SHA-256 of the supplied PDF: d1c9848a81d1e577aacb0e2666373e64b9f1ceb9e8aa29d9a545a7e343c4cee2